FY2024 EPS Estimates for Bruker Raised by Leerink Partnrs

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Bruker in a research note issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $2.39 for the year, up from their previous estimate of $2.38. The consensus estimate for Bruker’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $2.74 EPS, FY2026 earnings at $3.16 EPS and FY2027 earnings at $3.65 EPS.

Other equities research analysts have also recently issued research reports about the company. Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a report on Monday, September 30th. UBS Group started coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. Citigroup reduced their price objective on shares of Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research report on Friday, January 17th. Finally, Wells Fargo & Company reduced their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and an average price target of $74.45.

Bruker Stock Up 5.6 %

NASDAQ BRKR opened at $60.07 on Wednesday. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The stock has a market capitalization of $9.11 billion, a PE ratio of 28.88, a PEG ratio of 3.32 and a beta of 1.17. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The business’s 50-day moving average is $57.88 and its 200 day moving average is $61.62.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker’s revenue was up 16.4% on a year-over-year basis. During the same period last year, the business earned $0.74 EPS.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were issued a dividend of $0.05 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.33%. Bruker’s payout ratio is 9.62%.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien purchased 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The stock was purchased at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 28.30% of the company’s stock.

Institutional Trading of Bruker

Several institutional investors have recently bought and sold shares of BRKR. FMR LLC lifted its stake in shares of Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock worth $987,981,000 after buying an additional 2,521,904 shares in the last quarter. State Street Corp lifted its position in Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after acquiring an additional 318,808 shares in the last quarter. RTW Investments LP boosted its stake in Bruker by 1.1% during the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after purchasing an additional 37,024 shares during the last quarter. Geode Capital Management LLC boosted its stake in Bruker by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company’s stock worth $88,666,000 after purchasing an additional 779,549 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.